David J. Dabbs, MD
Professor of Pathology

Dr. Dabbs is Chief of Pathology at Magee-Womens Hospital of UPMC.
Office Location:
Rm. 4437
Magee-Womens Hospital
300 Haket Street
Pittsburgh, PA 15213

Contact Information:
Office Telephone: 412-641-4651
Email: ddabbs@mail.magee.edu

Research Interests

Dr. Dabbs has primary interest in breast pathology and immunohistochemistry. Dr. Dabbs is Editor and co-author of the soon-to-be-released First Edition of Breast Pathology (Spring, 2012, Elsevier, NY), a collaborative work of international contributors, the first book of its kind in the United States. Dr. Dabbs is also Editor and co-author of Diagnostic Immunohistochemistry, in its Third Edition (2010, Elsevier, NY). His expertise extends to gynecologic and surgical pathology, and he is currently the Chief Diagnostic Consultant for US Labs, based in Irvine, CA. Dr. Dabbs serves as Division Chief for Women's Heath, and is Chief of Pathology at Magee-Women's Hospital, and Director of the Magee Breast/Gynecologic Pathology Fellowship at Magee.

Selected Publications

View Dr. Dabbs' publications on PubMed

  1. Dual HER2 Gene Protein Assay: Focused Study of Breast Cancers With 2+ Immunohistochemical Expression.Li Z, Dabbs DJ, Cooper KL, Bhargava R. Am J Clin Pathol. 2015 Mar;143(3):451-8.
  2. Immunohistochemical Profile of Breast Cancer With Respect to Estrogen Receptor and HER2 Status. Gloyeske NC, Woodard AH, Elishaev E, Yu J, Clark BZ, Dabbs DJ. Appl Immunohistochem Mol Morphol. 2015 Mar;23(3):202-8.
  3. Simultaneous breast and axillary recurrence in a patient with a history of breast cancer and ipsilateral upper extremity melanoma: challenges in diagnosis and management. Ross M, Hadzikadic Gusic L, Dabbs DJ. Tumori. 2014 Jul-Aug;100(4):136e-9e
  4. Clark BZ, Beriwal S, Dabbs DJ, Bhargava R Semiquantitative GATA-3 Immunoreactivity in Breast, Bladder, Gynecologic Tract, and Other Cytokeratin 7-Positive Carcinomas. Am J Clin Pathol. 2014 Jul;142(1):64-71.PMID:24926087.
  5. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res. 2014 Mar 1;74(5):1463-74.PMID:24425047.
  6. Bhargava R, Dabbs DJ. Interpretation of Human Epidermal Growth Factor Receptor 2 (HER2) In Situ Hybridization Assays Using 2013 Update of American Society of Clinical Oncology/College of American Pathologists HER2 Guidelines. J Clin Oncol. 2014 Jun 10;32(17):1855.PMID:24778404.
  7. Gloyeske NC, Dabbs DJ, Bhargava R. Low ER+ breast cancer: Is this a distinct group? Am J Clin Pathol. 2014 May;141(5):697-701. PMID:24713741.
  8. Bright-Field HER2 Dual In Situ Hybridization (DISH) Assay vs Fluorescence In Situ Hybridization (FISH): Focused Study of Immunohistochemical 2+ Cases. Gao FF, Dabbs DJ, Cooper KL, Bhargava R. Am J Clin Pathol. 2014 Jan;141(1):102-10.
  9. Dabbs DJ, Schnitt SJ, Geyer FC et al. Lobular neoplasia of the breast revisited with emphasis on the role of e-cadherin immunohistochemistry. Am J Surg Pathol 2013 37(7) e1-11..
  10. Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, Bhargava R. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.Mod Pathol. 2013 Mar 15. [Epub ahead of print]
  11. Bhargava R, Dabbs DJ. Cancer of unknown primary origin: using ancillary techniques with caution. J Clin Oncol. 2013 Apr 10;31(11):1478-9.. Epub 2013 Feb 25.
  12. Jones MW, Onisko A, Dabbs DJ, Elishaev E, Chiosea S, Bhargava R. Immunohistochemistry and HPV in situ hybridization in pathologic distinction between endocervical and endometrial adenocarcinoma: a comparative tissue microarray study of 76 tumors. Int J Gynecol Cancer. 2013 Feb;23(2):380-4.
  13. Li X, Weaver O, Desouki MM, Dabbs DJ, Shyum S, Carter G, Zhao C. Microcalcification is an important factor in the management of breast intraductal papillomas diagnosed on core biopsy. Am J Clin Pathol. 2012 Dec;138(6):789-95 .
  14. Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, Jones MW, Chivukula M, Trucco GA, Bhargava R. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol. 2012 Dec;138(6):796-802.
  15. Li X, Kanbour-Shakir A, Dabbs DJ, Bhargava R. Morphologic Features Do Not Influence Response to Trastuzumab-containing Neoadjuvant Chemotherapy in HER2-positive Breast Cancer. Appl Immunohistochem Mol Morphol. 2012 Nov 15.
  16. Sikora MJ, Jankowitz RC, Dabbs DJ, Oesterreich S. Invasive lobular carcinoma of the breast: Patient response to systemic endocrine therapy and hormone response in model systems.Steroids. 2012 Nov 21.
  17. Adams AL, Dabbs DJ. Commonly encountered dilemmas in breast cancer reporting and staging. Semin Diagn Pathol. 2012 Aug;29(3):109-15.
  18. Yu J, Monaco SE, Onisko A, Bhargava R, Dabbs DJ, Cieply KM, Fine JL. A validation study of quantum dot multispectral imaging to evaluate hormone receptor status in ductal carcinoma in situ of the breast.
  19. Clark BZ, Dabbs DJ, Cooper KL, Bhargava R. Impact of Progesterone Receptor Semiquantitative Immunohistochemical Result on Oncotype DX Recurrence Score: A Quality Assurance Study of 1074 Cases. Appl Immunohistochem Mol Morphol. 2012 Oct 10. [Epub ahead of print]
  20. Zhao C, Desouki MM, Florea A, Mohammed K, Li X, Dabbs DJ. Pathologic Findings of Follow-up Surgical Excision for Lobular Neoplasia on Breast Core Biopsy Performed for Calcification. Am J Clin Pathol. 2012 Jul;138(1):72-8.
  21. Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, Chivukula M, McManus K, Bhargava R. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Am J Clin Pathol. 2012 May;137(5):691-8.
  22. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol. 2012 Mar 30 [Epub ahead of print]
  23. Kraus JA, Beriwal S, Dabbs DJ, Ahrendt GM, McGuire KP, Johnson RR, Badve P, Puhalla SL, Bhargava R. Predictors of Pathologic Complete Response After Standard Neoadjuvant Chemotherapy in Triple-negative Breast Carcinoma. Appl Immunohistochem Mol Morphol. 2012 Mar 12. [Epub ahead of print].
  24. Kraus JA, Dabbs DJ, Beriwal S, Bhargava R. Semi-quantitative immunohistochemical assay versus oncotype DX() qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol. 2012 Feb 3.: modpathol.2011.219. [Epub ahead of print]
  25. Bhargava R, Dabbs DJ. Oncotype DX Test on Unequivocally HER2-Positive Cases: Potential for Harm. Oncotype DX Test on Unequivocally HER2-Positive Cases: Potential for Harm. J. Clin Oncol. 2012 Feb 10;30(5):570-1. Epub 2012 Jan 9